Fig. 4: Dose response curve of maximal pAXL inhibition in AML blasts. | Nature Communications

Fig. 4: Dose response curve of maximal pAXL inhibition in AML blasts.

From: Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial

Fig. 4

AML blasts were identified within the peripheral blood mononuclear cell population by CyTOF and the maximum inhibition observed for each patient was plotted against the bemcentinib serum concentration at the time of maximum inhibition. A robust log-logistic dose response model with lower limit set to 0 was fitted. The calculated EC50 (+/- standard error) is indicated (text and dotted line). The black line indicates the fitted model, with the 95% confidence interval indicated by grey shading. n = 13 individual patients. Patients for whom maximum inhibition occurred before treatment onset are not shown because the corresponding serum concentration (0 ng/ml) cannot be accommodated on the logarithmic concentration scale. However, they were included for calculation of the dose response curve. Source data are provided as a Source Data file.

Back to article page